Zobrazeno 1 - 10
of 33
pro vyhledávání: '"MARY JANE GEIGER"'
Autor:
Markus Abt, B. Nhi Beasley, J. Rick Turner, Chakib Battioui, David H. Manner, Mary Jane Geiger, Stefan Hantel, Lee-Jen Wei
Publikováno v:
American heart journal. 215
Cardiovascular outcome trials (CVOTs) have been employed in multiple therapeutic areas to explore whether a noncardiovascular drug increases the risk for cardiovascular events. These studies are now a central part of drug development programs for ant
Autor:
Boaz Hirshberg, Boaz Mendzelevski, Christophe Arbet-Engels, Deborah R. Shapiro, J. Rick Turner, Murray Stewart, Stefan Hantel, Brenda Gaydos, Thomas G. Todaro, Joerg Koglin, Cyrus R. Mehta, Philip T. Sager, Mary Jane Geiger
Publikováno v:
Therapeutic innovationregulatory science. 49(1)
In December 2008, the US Food and Drug Administration (FDA) issued a guidance for industry requiring sponsors to demonstrate that a new antidiabetic therapy being developed to treat type 2 diabetes does not increase cardiovascular (CV) risk to an una
Autor:
Mary Beth Sabol, Philip T. Sager, Giuseppe Rosano, Mary Jane Geiger, Norman Stockbridge, Jonathan H. Seltzer, Kenneth W. Mahaffey, William B. White, J. Rick Turner
Publikováno v:
American Heart Journal. 169:197-204
This white paper provides a summary of presentations and discussions at a cardiovascular (CV) end point adjudication think tank cosponsored by the Cardiac Safety Research Committee and the US Food and Drug Administration (FDA) that was convened at th
Autor:
Keith C. Ferdinand, Eva Lonn, David A. Calhoun, Philip T. Sager, Kenneth E. Robertson, Mary Jane Geiger, Rebecca J. Threlkeld, William B. White, Rocco Brunelle, Honghua H. Jiang
Publikováno v:
Hypertension. 64:731-737
Glucagon-like peptide-1 receptor agonists, used to treat type 2 diabetes mellitus, are associated with small reductions in systolic blood pressure (SBP) and increases in heart rate. However, findings based on clinic measurements do not adequately ass
Autor:
Peter R. Kowey, Gary Gintant, Eric L. Michelson, Boaz Mendzelevski, George A. Mansoor, J. Rick Turner, Jeffrey Heilbraun, William B. White, Norman Stockbridge, Philip T. Sager, Mary Jane Geiger, Michael A. Weber
Publikováno v:
American Heart Journal. 165:477-488
This White Paper, prepared by members of the Cardiac Safety Research Consortium, discusses several important issues regarding the evaluation of blood pressure (BP) responses to drugs being developed for indications not of a direct cardiovascular (CV)
Autor:
Adel Nada, David E. Gutstein, Eric L. Michelson, Ignacio Rodriguez, Philip T. Sager, Luana Pesco Koplowitz, Mary Jane Geiger, Matthew Killeen, Glenn Carlson, Gary Gintant, Mónica L. Fiszman, Colette Strnadova, Christer Gottfridsson, Robert Kleiman
Publikováno v:
American Heart Journal. 165:489-500
Recent advances in electrocardiographic monitoring and waveform analysis have significantly improved the ability to detect drug-induced changes in cardiac repolarization manifested as changes in the QT/corrected QT interval. These advances have also
Autor:
Keith M. Channon, Stuart M. Grieve, Gemma A. Figtree, Hugh Watkins, Jiannis Ragoussis, Peter Collins, Bruce G. Robinson, Bridget Speller, Mary-Jane Geiger
Publikováno v:
Atherosclerosis. 199:354-361
Objective: Given the role of estrogen in the regulation of lipid metabolism, we screened for functional polymorphisms in the estrogen receptor alpha (ER), and examined for their influence on serum cholesterol. Methods and results: We identified a nov
Autor:
Marie T. Baccara-Dinet, Michel Farnier, Dirk J. Blom, Richard Ceska, Robert Dufour, Robert Pordy, John J.P. Kastelein, Jian Zhao, Henry N. Ginsberg, Michel Krempf, Daniel A. Gipe, Mary Jane Geiger, Fernando Civeira, Christelle Lorenzato, Gisle Langslet, G. Kees Hovingh
Publikováno v:
European Heart Journal
European Heart Journal, Oxford University Press (OUP): Policy B, 2015, 36 (43), pp.2996-3003. ⟨10.1093/eurheartj/ehv370⟩
European Heart Journal 43 (36), 2996-3003. (2015)
European heart journal, 36(43), 2996-3003. Oxford University Press
European Heart Journal, Oxford University Press (OUP): Policy B, 2015, 36 (43), pp.2996-3003. ⟨10.1093/eurheartj/ehv370⟩
European Heart Journal 43 (36), 2996-3003. (2015)
European heart journal, 36(43), 2996-3003. Oxford University Press
Aims To assess long-term (78 weeks) alirocumab treatment in patients with heterozygous familial hypercholesterolaemia (HeFH) and inadequate LDL-C control on maximally tolerated lipid-lowering therapy (LLT). Methods and results In two randomized, doub
Autor:
Claus Christiansen, Steven R. Cummings, Michelle A. Mcnabb, László B. Tankó, David A. Cox, Mary Jane Geiger
Publikováno v:
Journal of Bone and Mineral Research. 20:1912-1920
In the placebo group of the MORE study, including 2576 postmenopausal women (mean age, 66.5 years), the authors describe a strong linear association between the severity grade of osteoporosis (from low BMD to presence of severe vertebral fractures) a
Autor:
Elizabeth Barrett-Connor, David A. Cox, Mary Jane Geiger, Pandurang M. Kulkarni, Andreas Sashegyi, Jane A. Cauley
Publikováno v:
Journal of Bone and Mineral Research. 19:1270-1275
Posthoc analysis of the MORE osteoporosis treatment trial assessed risk-benefit profile of raloxifene in 7705 postmenopausal women. A major disease outcomes global index resulted in annual rates of 1.39% and 1.83% in the raloxifene and placebo groups